Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-47,988
Closed -$440K 5561
2025
Q1
$440K Sell
47,988
-7,880
-14% -$49.5K ﹤0.01% 4428
2024
Q4
$373K Buy
55,868
+3,976
+8% +$35K ﹤0.01% 4497
2024
Q3
$522K Sell
51,892
-299,716
-85% -$4.37M ﹤0.01% 4316
2024
Q2
$5.49M Buy
351,608
+66,054
+23% +$1.11M ﹤0.01% 3656
2024
Q1
$6.25M Sell
285,554
-8,063
-3% -$179K ﹤0.01% 3585
2023
Q4
$5.68M Buy
293,617
+15,092
+5% +$275K ﹤0.01% 3642
2023
Q3
$5.14M Buy
278,525
+18,308
+7% +$330K ﹤0.01% 3651
2023
Q2
$4.8M Buy
260,217
+216,415
+494% +$5.12M ﹤0.01% 3737
2023
Q1
$1.27M Buy
43,802
+1,961
+5% +$52.2K ﹤0.01% 4249
2022
Q4
$1.16M Sell
41,841
-2,155
-5% -$81.8K ﹤0.01% 4360
2022
Q3
$2.42M Sell
43,996
-5,423
-11% -$298K ﹤0.01% 4091
2022
Q2
$2.71M Sell
49,419
-2,074
-4% -$76.3K ﹤0.01% 4106
2022
Q1
$1.91M Buy
51,493
+1,478
+3% +$52.8K ﹤0.01% 4417
2021
Q4
$1.22M Buy
50,015
+1,339
+3% +$44.8K ﹤0.01% 4605
2021
Q3
$2.19M Buy
48,676
+7,855
+19% +$330K ﹤0.01% 4284
2021
Q2
$1.9M Sell
40,821
-122,834
-75% -$6.27M ﹤0.01% 4292
2021
Q1
$9.06M Buy
163,655
+7,245
+5% +$441K ﹤0.01% 3629
2020
Q4
$9.71M Sell
156,410
-15,605
-9% -$956K ﹤0.01% 3377
2020
Q3
$10.1M Buy
172,015
+4,607
+3% +$341K ﹤0.01% 3214
2020
Q2
$18.7M Buy
167,408
+19,541
+13% +$1.39M ﹤0.01% 2828
2020
Q1
$9.96M Sell
147,867
-810
-0.5% -$81.6K ﹤0.01% 2993
2019
Q4
$20.6M Buy
148,677
+14,996
+11% +$1.94M ﹤0.01% 2864
2019
Q3
$14M Buy
133,681
+5,753
+4% +$574K ﹤0.01% 3015
2019
Q2
$13.6M Buy
127,928
+17,578
+16% +$2.32M ﹤0.01% 3064
2019
Q1
$17M Sell
110,350
-10,994
-9% -$1.27M ﹤0.01% 2831
2018
Q4
$11.3M Buy
121,344
+49,557
+69% +$7.08M ﹤0.01% 3017
2018
Q3
$13.4M Buy
71,787
+5,303
+8% +$1.51M ﹤0.01% 3085
2018
Q2
$27.9M Buy
66,484
+51,235
+336% +$17.3M ﹤0.01% 2674
2018
Q1
$4.58M Sell
15,249
-102
-0.7% -$28.3K ﹤0.01% 3451
2017
Q4
$4.35M Buy
+15,351
New +$4.32M ﹤0.01% 3490

BlackRock's OPTN Position: Q2 2025 in Review

BlackRock sold out of OptiNose (OPTN) in Q2 2025, closing a stake of 47,988 shares — an estimated $440K sold.

BlackRock first reported a position in OPTN in Q4 2017 and held it in 30 quarters. The position peaked at $27.9M in Q2 2018. 0 funds tracked by Wall St. Rank hold OPTN as of Q2 2025.

  • BlackRock reported no remaining OptiNose position as of Q2 2025 after selling out during the quarter.
  • BlackRock sold 47,988 OptiNose shares in Q2 2025, an estimated $440K.
  • BlackRock first reported a position in OptiNose in Q4 2017 and held it in 30 quarters.
  • BlackRock's OptiNose position peaked at $27.9M in Q2 2018.
  • 0 funds tracked by Wall St. Rank held OptiNose as of Q2 2025.

Based on BlackRock's 13F filing for Q2 2025, filed 12 Aug 2025.